VLAP Stock Overview
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Valneva SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.68 |
| 52 Week High | €7.29 |
| 52 Week Low | €5.51 |
| Beta | 0.92 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -44.90% |
| 3 Year Change | 2.60% |
| 5 Year Change | 39.48% |
| Change since IPO | 1.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| VLAP | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 3.8% | 2.0% |
| 1Y | -44.9% | -23.3% | 4.5% |
Return vs Industry: VLAP underperformed the UK Biotechs industry which returned -28.7% over the past year.
Return vs Market: VLAP underperformed the UK Market which returned -2.4% over the past year.
Price Volatility
| VLAP volatility | |
|---|---|
| VLAP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: VLAP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine VLAP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 719 | Thomas Lingelbach | valneva.com |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
Valneva SE Fundamentals Summary
| VLAP fundamental statistics | |
|---|---|
| Market cap | €826.62m |
| Earnings (TTM) | -€135.36m |
| Revenue (TTM) | €372.96m |
2.2x
P/S Ratio-6.1x
P/E RatioIs VLAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VLAP income statement (TTM) | |
|---|---|
| Revenue | €372.96m |
| Cost of Revenue | €429.36m |
| Gross Profit | -€56.39m |
| Other Expenses | €78.97m |
| Earnings | -€135.36m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Sep 21, 2023
| Earnings per share (EPS) | -0.98 |
| Gross Margin | -15.12% |
| Net Profit Margin | -36.29% |
| Debt/Equity Ratio | 47.6% |
How did VLAP perform over the long term?
See historical performance and comparison